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BACKGROUND: HER2-positive metastatic breast cancer (MBC) relapsing after trastuzumab-based therapy may require continued HER2
receptor inhibition to control the disease and preserve the patients’ quality-of-life. Efficacy and safety of lapatinib monotherapy was
evaluated in Japanese breast cancer patients after trastuzumab-based therapies.
METHODS: In studies, EGF100642 and EGF104911 evaluated the efficacy and safety of oral lapatinib given 1500mg once daily in
patients with advanced or MBC. All patients progressed on anthracyclines and taxanes; HER2-positive patients had also progressed
on trastuzumab.
RESULTS: For HER2-positive tumours (n¼100), objective response rate was 19.0% (95% confidence interval (CI): 11.8–28.1) and
clinical benefit rate (CBR) was 25.0% (95% CI: 16.9–34.7). One out of 22 HER2-negative tumour was documented as complete
response (n¼22). The median time-to-progression (TTP) in the HER2-positive and HER2-negative groups was 13.0 and 8.0 weeks
(P¼0.007); median overall survival was 58.3 and 40.0 weeks, respectively. The most frequent adverse event was diarrhoea. TTP and
CBR were significantly associated with HER2 expression. Patients with tumours harbouring an H1047R PIK3CA mutation or low
expression of PTEN derived clinical benefit from lapatinib.
CONCLUSION: Lapatinib monotherapy had shown anti-tumour activity in Japanese patients with HER2-positive MBC that relapsed
after trastuzumab-based therapy, including those with brain metastases. Patients benefiting from lapatinib may have biomarker profiles
differing from that reported for trastuzumab.
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Approximately, 30% of invasive breast cancers (BC) overexpress
HER2, an adverse prognostic factor associated with aggressive
histopathological parameters and worse clinical outcome (Slamon
et al, 1987).
Despite the clinical breakthrough trastuzumab brought to the
treatment of HER2-overexpressing BC, the majority of metastatic
BC (MBC) does not respond to trastuzumab monotherapy, and
controversy remains over the optimal therapeutic strategy after
disease progression (Cobleigh et al, 1999; Vogel et al, 2002;
Montemurro et al, 2006). Intrinsic and acquired trastuzumab
resistance remains a concern (Nahta and Esteva, 2006; Xia et al,
2007). Additional concerns include increased incidence of brain
metastasis and risk of both short- and long-term cardiac toxicity
associated with trastuzumab therapy (Guarneri et al, 2006; Suter
et al, 2007).
Lapatinib, an orally active, small molecule, reversible inhibitor
of EGFR and HER2, is being evaluated for treatment of cancers
with EGFR expression and HER2 overexpression, including
cancers that are refractory to standard therapy. The simultaneous
blockade of both receptors by lapatinib may be more effective than
single receptor inhibition because of the propensity for HER family
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shetero-dimerisation and resultant signalling diversity (Mukherjee
et al, 2007). Lapatinib, as monotherapy or in combination with
chemotherapy, has promising anti-tumour activity in HER2
positive locally advanced or MBC as evidenced by efficacy outcome
reported earlier. Japan and many other countries showed that
lapatinib has efficacy in patients having HER2-positive BC with
brain metastases (Xia et al, 2002). From 44 clinical trials, safety
analysis indicated favourable cardiac toxicity profile of lapatinib
with a low frequency of asymptomatic events that are reversible
(Perez et al, 2008).
In Japan, two Phase II studies were conducted to evaluate the
efficacy and safety of lapatinib monotherapy in advanced or MBC
that had progressed on prior anti-tumour therapies, including
trastuzumab.
MATERIALS AND METHODS
Study design
EGF100642 and EGF104911 were multicentre, single-arm, open-
label studies involving 23 centres in Japan. Studies were designed
in accordance with the Japanese Ministry of Health, Labor and
Welfare Ordinance on Good Clinical Practice, to evaluate the
efficacy and safety of lapatinib in patients with advanced or MBC.
Studies were approved by the institutional review board of each
participating institution. All patients provided written informed
consent.
The primary endpoint was objective response rate (ORR:
confirmed complete response (CR) and partial response (PR))
according to response evaluation criteria in solid tumours
(RECIST) and determined by an independent review committee.
Secondary efficacy endpoints included clinical benefit rate (CBR:
CR, PR and stable disease (SD) for X24 weeks); time-to-progres-
sion (TTP); and overall survival (OS). In EGF100642, patients were
grouped, according to intra-tumoural HER2 expression, into
cohort A or B (HER2 positive and HER2 negative, respectively).
EGF104911 included patients with HER2-overexpressing tumours
only. The planned accrual for EGF100642 and EGF104911 was 100
patients (40 in cohort A; 60 in cohort B) and 52 patients, respec-
tively. Integrative analyses were conducted on efficacy, safety and
biomarker data from the two studies.
Patient eligibility
Eligible patients were female aged 20–74 years with confirmed
advanced (stage IIIb or IIIc with T4 lesion) or MBC that had
progressed on prior anthracycline- and taxane-containing regi-
mens. All patients with HER2 overexpression had received X6
weeks of prior trastuzumab. Eligible patients had measurable
lesions as defined by RECIST; an Eastern Cooperative Oncology
Group (ECOG) performance status of 0–2; left ventricular ejection
fraction (LVEF) within the institutional normal range (or X50%);
adequate renal, hepatic and haematologic functions.
Treatment schedule
Lapatinib 1500mg was taken orally once daily in fasted conditions.
Patients were treated until disease progression, unacceptable
toxicity or consent withdrawal.
Efficacy and safety assessments
Safety and efficacy assessments (including echocardiogram for
LVEF) were performed at 4- and 8-week intervals, respectively, at
treatment completion and 28 days after the last dose. All patients
were followed for survival every 12 weeks until death. Adverse
events (AEs) were assessed according to the National Cancer
Institute Common Terminology Criteria for AEs version 3.0 (NCI
CTCAE v3.0).
Immunohistochemistry and fluorescent in situ
hybridisation
Formalin-fixed, paraffin-embedded (FFPE) archived tumour tissue
blocks (or sections) were required for enrolment. Intra-tumoural
protein expression levels were determined by immunohistochemistry
(IHC) and reported as an H-score (McCarty et al, 1986) excluding
EGFR and HER2, which were reportedb yt h ea s s a yd e f i n e do r d i n a l
score (Dako, Carpinteria, CA, USA). The following antibodies were
used in the semi-quantitative IHC assays performed at Quest
Diagnostics (Van Nuys, CA, USA): HER2 (HercepTest, Dako); EGFR
(PharmDx, Dako) and at Pathway Diagnostics (Malibu, CA, USA):
ErbB3 (NeoMarkers RB-9211, Thermo Fisher, Fremont, CA, USA);
ErbB4 (#18-7329, Zymed, South San Francisco, CA, USA); IGF1R
(NeoMarkers MS-641, Thermo Fisher); BCL2 (Dako). PTEN (Cell
Signaling Technology, Danvers, MA, USA, #9559) analysis was
performed at European Institute of Oncology (Milan, Italy).
Deoxyribonucleic acid (DNA) fragmentation (TUNEL) was measured
at Pathway Diagnostics using the ApopTag in situ assay (Chemicon
International, Temecula, CA, USA). Oestrogen (ER) and progesterone
(PgR) receptor results were from local laboratories and reported as
positive or negative. HER2 gene amplification was determined by
fluorescence in situ hybridisation (FISH) using the PathVysion kit
(Vysis, Downers Grove, IL, USA) at Quest Diagnostics.
Mutation assessments
DNA was extracted from FFPE tumour tissue; seven of the exons
comprising the kinase domain of PIK3CA (exons 14–20) and exon 9
(helical domain) were amplified by polymerase chain reaction and
sequenced using the ABI3730XL sequencer (Applied Biosystems,
Foster City, CA, USA); somatic single nucleotide polymorphisms
(SNPs) were identified by sequence analysis and mapping the results
to the PIK3CA GenBank reference sequence NM_006218.
HER2 extracellular domain
Serial blood samples were collected at baseline, every 4 weeks, and
at study conclusion. Serum HER2 extracellular domain (ECD)
levels were analysed at Quest Diagnostics using an HER-2/neu
Microtiter enzyme-linked immunosorbent assay kit from Onco-
gene Science (Cambridge, MA, USA).
Statistical design and analysis
The hypotheses for both studies were based on expected ORR
(X15%), accordingly the sample sizes (calculation using SAS
version 8.2, UNIX/Solaris) ensured X74% power to deem lapatinib
monotherapy effective by correctly rejecting the null hypothesis
(H0: Po0.05) and accepting the alternative hypothesis (H1:
P40.15). The efficacy endpoints were estimated using two-sided
95% confidence interval (CI); TTP and OS were summarised using
the Kaplan–Meier method.
Biomarkers were related to TTP using Cox proportional hazards
models, and to clinical response using logistic regression. Corre-
lations between biomarkers were evaluated using Spearman’s rank
correlation coefficient. Statistical tests were considered significant
if Po0.05. Analyses were conducted using SAS v9.1.3.
RESULTS
Patients
Between June 2004 and October 2006, 122 patients (64 and 58 from
EGF100642 and EGF104911, respectively) were enroled; 100 had
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positive) and 22 (cohort B) had HER2-negative tumours (defined
as IHC 0/1þ or FISH negative). Although the planned patient
number for cohort B was 60, accrual stopped based on minimal
efficacy of lapatinib monotherapy reported in HER2-negative BC
(Burstein et al, 2008). Out of 122 patients, 119 discontinued
therapy; 108 (91%) because of disease progression, 8 (7%) because
of AEs and 3 (3%) withdrew consent. Three patients with HER2-
positive tumours remained on study treatment.
Patient baseline characteristics are shown in Table 1. Over 80%
had at least three prior anti-tumour regimens. All patients received
prior anthracyclines and taxanes. All but 2% of HER2-positive
patients had previously received trastuzumab for advanced or
metastatic disease. The majority (75%) had received trastuzumab
within 8 weeks before enrolment.
The median duration of treatment was 13.9 weeks in patients
with HER2-positive tumours and 7.4 weeks in those with HER2-
negative tumours.
Efficacy
In HER2-positive patients, 1 CR (1%) and 18 PRs (18.0%) were
documented, for an ORR of 19.0% (95% CI: 11.8–28.1); SD and
progressive disease (PD) were observed in 38% (38 out of 100) and
41% (41 out of 100), respectively; two patients had an unknown
response. In patients with HER2-negative tumours only one
patient responded (CR; ORR¼4.5%), the majority (68%) had PD
and 14% had short-term SD. CBR in HER2-positive patients was
25.0% (95% CI: 16.9–34.7) and 4.5% in HER2-negative patients.
The median TTP was 13.0 weeks (25th, 75th percentiles: 7.8, 24.1)
in HER2-positive patients and 8.0 weeks (25th, 75th percentiles:
5.4, 8.4) in HER2-negative patients. The median OS was 58.3 weeks
(25th, 75th percentiles: 26.2, 64.8) in HER2-positive patients and
40.0 weeks (25th, 75th percentiles: 18.3, 69.3) in HER2-negative
patients.
In the HER2-positive group, 10 patients had brain metastases at
baseline, 8 had no brain lesion progression of these 2 had ORR of
PR, whereas brain lesions progressed in 2 patients.
Safety
Among 122 patients evaluable for safety, 120 (98.4%) experienced
at least 1 AE, most were Grade 1 or 2. The Grade 4 AEs (increased
bilirubin and g-glutamyl transferase) occurred in a patient with
concurrent progression of liver metastases. The AEs with X20%
incidence are presented in Table 2.
There were 27 non-fatal serious AEs in 19 patients, 13 were
possibly related to lapatinib. The only lapatinib-related serious
AEs occurred in more than one patient were anorexia (n¼3, 2.5%)
and left ventricular dysfunction (n¼2, 1.6%). Both patients
experiencing left ventricular dysfunction remained on lapatinib
and the event later resolved.
Three patients died because of disease progression. One patient
experienced fatal AEs (increase in g-glutamyl transferase and
bilirubin); the events, deemed unrelated to lapatinib, were due to
liver metastases progression. The other two experienced ‘unexpec-
tedly rapid’ disease progression; one in a HER2-negative patient.
Biomarkers
The following biomarkers had results available in 95–100% of
tumour samples: EGFR; HER2 (Table 3); ER; PgR. ErbB3, PTEN,
IGF1R and BCL2 were well represented for EGF100642 (480%),
but were sparse for EGF104911 (p40%). The remaining biomarkers:
Heregulin, TUNEL and Survivin, were represented in 55% or fewer
samples, with particular scarcity in EGF104911 (o20%).
The HER2 IHC score was strongly associated with TTP
(P¼0.0083, Figure 1). TTP increased monotonically with increas-
ing HER2 IHC score. CBR was higher in HER2 IHC 2þ and 3þ
tumours (P¼0.0168). The proportion of patients deriving clinical
benefit from lapatinib in IHC 0, 1þ,2þ and 3þ groups was 4%
(1 patient), 0%, 23%, and 73%, respectively. In 23% of patients
experiencing clinical benefit from lapatinib and with IHC2þ
tumours, all were HER2 FISH positive.
TTP and CBR differed between the studies. HER2-positive
patients in EGF100642 experienced longer TTP compared with
EGF104911 (P¼0.0212, Figure 2). Cohort A (EGF100642) had a
higher CBR than EGF104911 (P¼0.0385, Table 4). The efficacy
differences between the studies may be explained by the difference
in the frequency of ER and PgR expression. In EGF100642, 17% of
HER2-positive tumours were ER positive, whereas 43% were ER
positive in EGF104911; PgR positive was detected in 15% and 35%,
respectively. Although CBR was not significantly associated with
hormone receptor status (P¼0.100), PgR status had a significant
effect on TTP (P¼0.016), whereas ER status did not (P¼0.3188).
Patients with PgR-positive tumours regardless of ER status
(n¼26) had the shortest median TTP (8.4 weeks), whereas
patients with PgR-negative tumours had similar median TTP
(15.4 weeks for ERnegative, PgR negative, n¼60; 17 weeks for ER
positive, PgR negative, n¼12).
EGFR and IGF1R expression were not significantly associated
with efficacy parameters. IGF1R expression did not preclude
patients from deriving benefit from lapatinib (n¼58, P¼0.3394,
Figure 3A). PTEN expression did not associate with lapatinib
response; in patients with HER2-positive tumours (EGF100642,
n¼36), CBR was not dependent on PTEN (P¼0.9093), thus
patients with tumours expressing low levels of PTEN derived
benefit from lapatinib (Figure 3B).
Table 1 Patient characteristics – demographics and disease history
Characteristic
HER2
positive
n¼100
HER2
negative
n¼22
Total
population
n¼122
Median age, years 55.0 52.5 55.0
ECOG PS, n (%)
0–1 97 (97) 19 (86) 116 (95)
2 3 (3) 3 (14) 6 (5)
Disease stage, n (%)
IIIB/IIIC (T4) 1 (1) 2 (9) 3 (2)
IV 99 (99) 20 (91) 119 (98)
Prior anti-tumour therapy, n (%)
Anthracyclines 100 (100) 22 (100) 122 (100)
Taxanes 100 (100) 22 (100) 122 (100)
Trastuzumab 100 (100) 0 100 (82)
Neoadjuvant
a 2 (2) 0 2 (2)
Adjuvant
b 4 (4) 0 4 (3)
Advanced/metastatic 98 (98) 0 98 (80)
No. of metastatic sites, n (%)
X3 43 (43) 9 (41) 52 (43)
2 36 (36) 6 (27) 42 (34)
1 21 (21) 7 (32) 28 (23)
Hormone receptor status, n (%)
ER+ and/or PgR+ 38 (38) 14 (64) 52 (43)
ER  and PgR  60 (60) 8 (36) 68 (56)
Unknown (ER and/or PgR) 2 (2) 0 2 (2)
Abbreviations: ECOG PS¼European Cooperative Oncology Group Performance Status;
ER¼oestrogen; PgR¼progesterone.
aPatients received trastuzumab for neoadjuvant
and advanced/metastatic setting.
bTwo patients received trastuzumab for adjuvant
and advanced/metastatic disease, two patients received in adjuvant setting only.
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tion with each other in the HER2-positive patients. Significant
correlations were found between BCL2 and IGF1R (r¼0.33,
P¼0.015), ErbB3 and Heregulin (r¼0.39, P¼0.012) and IGF1R
and PTEN (r¼0.62, P¼0.0003).
Biomarkers were compared with ER and PgR status in HER2-
positive patients using the Wilcoxon rank sum test. BCL2 levels
were significantly higher in ER-positive patients (n¼52, P¼0.017)
and PgR-positive patients (n¼51, P¼0.025). Heregulin (n¼40,
P¼0.005) and Survivin (n¼22, P¼0.047) were found to be higher
in PgR-negative patients.
PIK3CA gene (exon 9; 14–20) mutation analysis was conducted
in EGF100642; 30 tumour samples had sufficient quantities for of
genomic DNA. Owing to the low quantities of genomic DNA in all
tumour samples, exon 20 was the highest priority because of the
presence of the well-characterised H1047R kinase-activating
mutation located in this exon and detected in BC (Kang et al,
2005). Exon 20 mutation analysis was completed in 29 samples; in
3 tumours the H1047R mutation was detected. Lapatinib response
in the three patients (HER2 positive) whose tumours harboured
the H1047R mutation included one durable PR (32 weeks), and two
SD (16 weeks). Mutation analysis on the remaining exons identi-
fied two SNPs in two different tumour samples resulting in non-
conservative amino acid substitutions (exon 15: E767K; exon 18:
T898I). Although both substitutions were predicted to be struc-
turally tolerated and speculated to not directly affect PIK3CA
kinase activity, the indirect functional implications were unknown.
The patients whose tumours contained these SNPs derived clinical
benefit from lapatinib: one (HER2 positive) SD for X24 weeks; one
(HER2 negative) CR for 23 weeks. In tumours with evaluable
results (10 out of 30), no SNPs resulting in an amino acid change
were detected in exon 9.
The distribution of baseline serum ECD (bECD) values showed
that levels appear to be higher in patients with HER2-positive
tumours (median: 44.5ngml
 1; 25th, 75th percentiles: 15.2, 114.3)
vs HER2-negative tumours (median: 9.9ngml
 1; 25th, 75th per-
centiles: 8.0, 12.4); however, bECD did not predict response. After
adjusting for HER2 status in the pooled sample, bECD (entered
Table 2 Incidence of common adverse events reported in X20% of patients by maximum NCI CTCAE toxicity grade
All grades Grades 3/4
MedDRA preferred term No patients % Number of patients %
Any event 120 98.4 41 33.6
Diarrhoea 86 70.5 7 5.7
Rash 59 48.4 1 0.8
Stomatitis 54 44.3 0 0
Nausea 48 39.3 1 0.8
Anorexia 48 39.3 10 8.2
Fatigue 47 38.5 4 3.3
Pruritus 36 29.5 0 0
Nasopharyngitis 33 27.0 0 0
Aspartate aminotransferase increased 28 23.0 5 4.1
Dry skin 27 22.1 0 0
Vomiting 27 22.1 2 1.6
Pyrexia 24 19.7 1 0.8
Weight decreased 22 18.0 0 0
Alanine aminotransferase increased 21 17.2 3 2.5
Blood alkaline phosphatase increased 20 16.4 4 3.3
Dyspnoea 20 16.4 2 1.6
Abbreviations: MedDRA¼Medical Dictionary for Regulatory Activities; NCI CTCAE¼National Cancer Institute Common Terminology for Adverse Events.
Table 3 Distribution of EGFR and HER2 biomarker IHC scores
EGF100642 EGF104911
HER2 positive
a (n¼42) HER2 negative (n¼22) HER2 positive
a (n¼58)
HER2 IHC score, n (%)
0 0 16 (73) 2 (3)
1+ 2 (5) 5 (23) 4 (7)
2+ 6 (14) 1 (5) 19 (33)
3+ 34 (81) 0 (0) 33 (57)
FISH amplification, n (%)
Positive (X2) 39 (93) 1 (5) 53 (91)
Negative (o1.8) 0 7 (32) 1 (2)
b
Non-evaluable 3 (7)
c 13 (60) 3 (5)
b
Borderline (1.8–o2) 0 1 (5)
d 1 (2)
b
EGFR IHC score, n (%)
0 30 (71) 19 (86) 46 (79)
1+ 7 (17) 2 (9) 10 (17)
2+ 5 (12) 1 (5) 1 (2)
3+ 0 0 1 (2)
aHER2 eligibility was determined by site local laboratory data.
bFISH-negative tumour was IHC 0; non-evaluable: one was IHC 0, one was IHC1+, one was IHC3+; borderline was
IHC2+.
cFISH non-evaluable tumours: one was IHC1+, one was IHC2+, one was IHC3+.
dFISH borderline tumour was IHC 0.
Lapatinib monotherapy in cancer patients
M Toi et al
1679
British Journal of Cancer (2009) 101(10), 1676–1682 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
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TTP in a proportional hazards model (P¼0.568). In a similar
model, neither were bECD levels predictors of TTP within HER2-
negative (P¼0.531) or HER2-positive patients (P¼0.582), nor
were bECD levels predictors of TTP in the HER2-positive patients
when adjusted for ER/PgR status (P¼0.896).
DISCUSSION
Lapatinib monotherapy was efficacious in treating HER2-over-
expressing advanced or MBC that relapsed after trastuzumab
treatment. Lapatinib benefit was confined mostly to HER2-positive
tumours (ORR was 19%; CBR was 25.0%) and confirmed previous
reports (Geyer et al, 2006; Gomez et al, 2008). In this heavily
pretreated population with refractory HER2-positive BC, treat-
ment with single-agent lapatinib resulted in a median TTP of 13.0
weeks and median OS of 58.3 weeks. Median progression-free
survival was identical to TTP (13.0 weeks for the HER2-positive
population), as no time-to-event at the time of data cut-off
occurred because of death.
TTP and CBR differed between the studies. Patient character-
istics were similar in both studies except for differences observed
in the distribution of patients with hormone-receptor-positive BC,
although expression was not confirmed by central review. This
small dataset suggests that lapatinib may affect TTP based on PgR
status. PgR expression and activity, whereas dependence on
classical ER genomic signalling has been shown to be regulated
by growth factor signalling (Arpino et al, 2008). Additional reports
have suggested that negative PgR expression indicates high growth
factor activity (Cui et al, 2005). Perhaps in the context of HER2
overexpression and ER positivity, low or absent PgR expression
may be a predictor of tumour dependence on HER2 activity and
thus sensitivity to HER2 inhibition with agents such as lapatinib.
Lapatinib response may be independent of PTEN, PIK3CA and
IGF1R, as supported by lapatinib responses observed in these
studies and demonstrated in preclinical studies (Nahta et al, 2007;
Xia et al, 2007). Patients with HER2-positive tumours having
PIK3CA amino acid changes derived benefit from lapatinib.
Additionally, patients with low PTEN, or expressing IGF1R also
derived benefit from lapatinib. These findings, albeit in a small
cohort, suggested that lapatinib anti-tumour activity may depend
on a cellular milieu different from trastuzumab, which reportedly
has decreased activity in tumours with the aforementioned
characteristics (Nahta and Esteva, 2006). Ongoing clinical trials
in early and advanced BC have been designed to elucidate lapatinib
mechanism of action, identify predictive biomarkers and further
define the differences in activity compared with other HER2
inhibitors.
In the HER2-negative cohort, one patient experienced a durable
CR (23 weeks) and had a primary tumour with the following mole-
cular characteristics: HER2 negative and EGFR negative; ER posi-
tive and PgR positive; low expression of PTEN and PIK3CA
(E767K) SNP. Biomarker evaluations were performed on the pri-
mary tumour and not the recurrent site; hence, it is interesting to
speculate that the genotype/phenotype of treated tumour was
modified at recurrence, supporting the practicing biopsy on
relapse.
Brain metastases is an area of significant unmet medical need, as
up to one-third of HER2-overexpressing MBC patients develop
central nervous system metastases after trastuzumab treatment
(Bendell et al, 2003; Clayton et al, 2004). In this study, 10 patients
had brain metastases at baseline and of these 8 experienced either
systemic PR or SD, indicating that lapatinib monotherapy is
efficacious in HER2-positive BC patients with brain metastases,
thus supporting previous reports (Lin et al, 2008).
Trastuzumab treatment is associated with cardiac dysfunction,
with up to 28% of patients experiencing such events (Guarneri
et al, 2006), although asymptomatic LVEF declines were more
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Figure 1 Kaplan–Meier estimates for TTP in the combined studies. TTP
is stratified by HER2 IHC Score. Median IHC 0/1¼8 weeks; IHC 2þ¼12
weeks; IHC 3þ¼16 weeks. (log rank P¼0.0083); 23 out of 26 HER2
IHC2þ tumours were FISH positive, 3 out of 26 tumours were non-
evaluable by FISH.
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Figure 2 Kaplan–Meier estimates for TTP. TTP is significantly longer in
EGF100642 HER2-positive patients vs EGF104911 patients (median TTP
for EGF100642¼16.3 weeks; EGF104911¼8.4 weeks; P¼0.0212).
Table 4 Best response by study and cohort
EGF100642 EGF104911
HER2 positive
(n¼42)
HER2 negative
(n¼22)
HER2 positive
(n¼58)
Best response, n (%)
CR 0 1 (5) 1 (2)
PR 10 (24) 0 8 (14)
SD 20 (48) 3 (14) 18 (31)
PD 12 (29) 15 (68) 29 (50)
NE 0 3 (14) 2 (3)
CBR 16 (38) 1 (5) 11 (19)
Abbreviations: CR¼complete response; PR¼partial response; SD¼stable disease;
PD¼progressive disease; NE¼non-evaluable; CBR¼clinical benefit rate (CR; PR;
SD X24 weeks).
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scommon than symptomatic heart failure (Marty et al, 2003). In this
study, three patients experienced LVEF decrease (2.4%); however,
with mild severity (Grade 1). These data were similar to that
observed from 44 lapatinib clinical trials, in which the incidence
was reported as 1.6% (60 out of 3689 lapatinib-treated patients)
(Perez et al, 2008).
The results in Japanese patients showed that lapatinib was well
tolerated and an effective treatment for HER2-positive BC
(ORR¼19%; CBR¼25%), despite disease progression on trastu-
zumab-based therapy. Although low ORR (4.3; 7.7%) were
observed in similar patient populations who were mostly
Caucasian (Burstein et al, 2008; Blackwell et al, 2009); however,
neither intrinsic nor extrinsic factors were evaluated to determine
the efficacy differences. In first-line patients with trastuzumab-
naı ¨ve, HER2-positive advanced or MBC, lapatinib monotherapy
resulted in 24% ORR (Gomez et al, 2008). Lapatinib combination
therapy has promising efficacy as treatment for HER2-positive
advanced or MBC, including treatment-naı ¨ve MBC (Geyer et al,
2006; Di Leo et al, 2008; O’Shaughnessy et al, 2008; Johnston et al,
2008a,b). The outcome of this study complements the efficacy
reported earlier for lapatinib and confirms that lapatinib offers a
beneficial therapeutic option to patients with HER2-overexpressing
BC, including those with brain metastases. The efficacy for the
tumours having the altered PI3K pathway may provide a novel
possibility in the treatment of HER2-positive BCs.
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